Lancet. 1996 Dec 14;348(9042):1605-10.
Survival rates after surgery for rectal cancer remain at about 40% at 5 years from diagnosis. The aim of this study was to find out whether local recurrence rate could be reduced and survival increased by a moderately high dose of preoperative radiotherapy in patients with locally advanced, but otherwise operable, carcinoma of the rectum.
We carried out a prospective randomised trial of surgery alone (n = 140) versus surgery preceded by 40 Gy radiotherapy (n = 139) given in 20 fractions of 2 Gy over 4 weeks. The patients, from 20 regional centres throughout the UK, were enrolled between 1981 and 1989, and followed up for a minimum of 5 years or to death.
217 patients died, 114 of 140 allocated surgery alone and 103 of 139 allocated preoperative radiotherapy: median survival times were 24 months and 31 months, respectively. The hazard ratio for overall survival was 0.79 (95% CI 0.60-1.04, p = 0.10). At 5 years' follow-up 65 patients allocated surgery alone and 50 who received preoperative radiotherapy had local recurrence (hazard ratio 0.68 [0.47-0.98], p = 0.04); the corresponding numbers of patients with distant recurrence were 67 and 49 (hazard ratio 0.66 [0.46-0.95], p = 0.02). There was a significant benefit of radiotherapy on disease-free survival (hazard ratio 0.76 [0.58-1.0], p = 0.05). There was no increase in postoperative or late complications in the radiotherapy group.
Our results provide further evidence that preoperative radiotherapy can reduce the rate of local recurrence of rectal cancer in patients with locally advanced disease. However, survival results are still equivocal, and so we must await the results of a meta-analysis of all radiotherapy trials from which precise and definitive results, particularly for survival, may be obtained.
直肠癌手术后的5年生存率自诊断起仍维持在约40%。本研究的目的是探究对于局部晚期但仍可手术切除的直肠癌患者,适度高剂量的术前放疗是否能够降低局部复发率并提高生存率。
我们进行了一项前瞻性随机试验,对比单纯手术组(n = 140)与术前接受40 Gy放疗组(n = 139),放疗在4周内分20次给予,每次2 Gy。来自英国20个地区中心的患者于1981年至1989年入组,并随访至少5年或直至死亡。
217例患者死亡,单纯手术组140例中有114例死亡,术前放疗组139例中有103例死亡:中位生存时间分别为24个月和31个月。总生存的风险比为0.79(95%可信区间0.60 - 1.04,p = 0.10)。在5年随访时,单纯手术组65例患者和接受术前放疗的50例患者出现局部复发(风险比0.68 [0.47 - 0.98],p = 0.04);远处复发的相应患者数分别为67例和49例(风险比0.66 [0.46 - 0.95],p = 0.02)。放疗对无病生存有显著益处(风险比0.76 [0.58 - 1.0],p = 0.05)。放疗组术后或晚期并发症未增加。
我们的结果进一步证明,术前放疗可降低局部晚期直肠癌患者的局部复发率。然而,生存结果仍不明确,因此我们必须等待所有放疗试验的荟萃分析结果,从中可能获得精确和明确的结果,尤其是关于生存的结果。